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1. Introduction 
Over the past 20 years, implant therapy has been used as an alternative to tooth 
replacement, to retain removable appliances, and to support fixed prostheses.  Implant 
therapy has become the gold standard in tooth replacement with over four and a half 
million implants placed each year across the globe.  While osseointegration of dental 
implants occurs in more than 90% of the cases[1], once exposed into the oral cavity, 
implants will be immediately colonized by bacterial plaque[2].  The consequent 
interaction of the bacterial biofilm with the peri-implant soft tissue interface results in an 
inflammatory reaction.  The inflammatory state around the implant mucosa has been 
termed mucositis.  The periodontal literature has extensively characterized the tissue 
response to the biofilm formed around the natural dentition.  However, it is still unclear 
whether the tissue response to bacterial biofilm around the natural dentition differs to that 
around implants.   
Peri-implant mucositis is defined as a reversible inflammatory process involving the soft 
tissue surrounding an implant without accompanying bone loss[3].  The prevalence of 
peri-implant mucositis is estimated at 79.2% of patients and 42.2% of implants[4].  
Evidence from animal studies supports that a persistent inflammatory condition may 
progress to peri-implantitis[3, 5, 6] and eventually to implant loss.   
The biological processes regulating the inflammatory response in the peri-implant 
mucosa are not clearly defined.  Several studies have shown a similar response in the 
tissue around both teeth and implants to bacterial plaque[7-9].  At the same time, other 
studies have demonstrated differences between teeth and implant soft tissue in terms of 
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the immune response[10], the quality and quantity of the inflammatory infiltrate[8], and 
the quality of the microbial flora[11].  This study utilizes a human model of experimental 
peri-implant mucositis to evaluate the progression of the inflammatory process of the soft 
tissue around implants and to compare that to the inflammatory process of gingiva around 
teeth.  This thesis seeks to clarify how the peri-implant mucosa and gingiva compare in 
response to undisturbed plaque accumulation, using clinical indices of health and disease.   
2. Background and Significance 
2.1 Gingivitis 
2.1.1 Definition and Prevalence 
Gingivitis is defined as the presence of gingival inflammation without the loss of 
connective tissue attachment[12].  The prevalence of gingivitis is difficult to quantify.  
This is partly due to a deficient methodology to objectively measure gingival 
inflammation.   However, several studies attempted to quantify the prevalence of 
gingivitis in America[13, 14].   
The 3rd National Health and Nutrition Examination Survey (NHANES III) conducted in 
1988-1991 gives us some measure to determine the prevalence of gingivitis.  However, 
NHANES III did not directly attempt to quantify gingivitis.  The data collected included 
bleeding on probing, which we can then correlate to a moderate inflammation using the 
index for assessment of gingivitis introduced by Löe and Silness[15].  The periodontal 
evaluation in NHANES III included a total of 7,447 dentate individuals 13 years and 
older.  The examinations were partial-mouth periodontal exams, performed on two 
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randomly selected quadrants, on 2 sites per tooth, with a maximum of 14 permanent teeth 
eligible for assessment (third molars were excluded).  Brown et al. [13] reported that 
bleeding on probing was found in 62.9% for all persons aged 13 and older.  However, 
these data have to be considered with caution, since a partial-mouth periodontal 
assessment has been shown to underestimate the prevalence of the disease[16].  
Furthermore, the criteria to detect gingivitis include the visible signs of color change and 
texture.  Thus, a large percentage of individuals with gingivitis without bleeding on 
probing were not included in the above statistic.  A recent study by Li et al. [14] sought to 
determine the prevalence of gingivitis in American adults using the Löe and Silness 
Gingival Index (GI) and found that 93.9% of individuals had a mean GI > 0.50.  This 
percentage decreased to 55.7% for individuals with a mean GI ≥ 1.0.  These studies 
suggest that the prevalence of gingivitis in the American population ranges between 
55.7% and 93.9% depending on the definition used and method of calculation.    
2.1.2 Etiology 
The etiology of gingivitis was elegantly demonstrated in 1965 by Löe [17] (see section 
2.1.4).  In this experiment, a direct cause and effect relationship was found between 
plaque accumulation and gingival inflammation.  Hence, this study offered proof that 
bacterial biofilm causes gingivitis[17]. 
 Under experimental gingivitis conditions, a significant shift was observed in the bacterial 
composition from health to gingivitis[17].  The bacteria of healthy gingiva were 
composed predominately of Gram-positive cocci and rods.  When localized gingivitis 
was first clinically detectable (GI = 1 on one tooth surface), Gram-negative cocci and 
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rods were found in increasing percentages in the microflora.  There was a shift again as 
generalized gingivitis was clinically identified (GI = 1 for the individual).  Here, Gram-
positive and negative filaments, fusobacteria, spirilla, and spirochetes were more readily 
measurable.  In the study by Theilade et al. [18] a correlation between gingival status and 
plaque composition was established.  Theilade’s work details the growing complexity of 
the microflora composition as plaque accumulates[18, 19].  The authors’ results indicate 
that gingivitis is not due to an infection by a single pathogen, but rather a plaque ecology 
that is unfavorable to the host[20].   
2.1.3 Histopathology 
The histological features of healthy gingiva include a keratinized oral epithelium 
continuous with a junctional epithelium (JE) that is attached to the tooth surface by 
hemidesmosomes.  Polymorphonuclear leukocytes (PMN), while small in overall number, 
are present in the healthy sulcus as a normal reaction to the biofilm present around teeth 
even in a meticulously cleaned mouth[21].  If sufficient plaque is allowed to accumulate, 
gingivitis will ensue.  Page and Schroeder described the pathogenesis of gingivitis and 
periodontitis as a continuum of increasing inflammatory response by the host to microbial 
plaque[21]. 
The first stage of gingivitis is the initial lesion.  It is formed within 2-4 days of the 
initiation of plaque accumulation.  The characteristics of the initial lesion are vasculitis 
adjacent to the JE, increased flow of gingival crevicular fluid (GCF), and increased 
migration of PMNs into the JE and sulcus.  Additionally, an altered morphology of 
epithelial cells in the coronal part of the JE and loss of perivascular collagen can be seen.  
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Neutrophils adhere to vessel walls and migrate to the connective tissue, JE, and sulcus.  
At this stage bacterial invasion is not evident and the inflammatory response is thought to 
be related to plaque-derived chemotactic substances[21].   
The second stage of gingivitis is called the early lesion.  It is mostly an accentuation of 
the initial lesion and occurs at days 4 through 7.  There is an accumulation of lymphoid 
cells (approximately 75% of the total infiltrate) adjacent to the JE, further loss of collagen 
fiber network supporting the marginal gingiva and the beginning of proliferation of the 
basal cells of the JE.  The primary distinguishing feature here is the migration of 
lymphoid cells (predominately T cells with very few B cells) into the lesion[21].  
The third and final stage of gingivitis is the established lesion.  It is formed at least 7 days 
after the initiation of plaque accumulation.  The histo-pathological hallmark of this 
condition is the predominance of plasma cells.  Immunoglobulins are seen 
extravascularly in the connective tissues and JE.  There is a continuing loss of connective 
tissue matrix elements and proliferation, apical migration, and lateral extension of the JE 
leading to the formation of a pocket epithelium[21].  This established lesion can remain 
stable for months or years without progressing.  The established lesion is still reversible.  
Further persistence of the established lesion may eventually progress to the advanced 
lesion, which is defined as irreversible and accompanied by attachment loss.  Once 
attachment loss occurs, the condition is defined as periodontitis.    
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2.1.4 Experimental Gingivitis 
The model of experimental gingivitis, which requires patients to refrain from oral 
hygiene measures for a period of time, was first proposed by Löe et al.[17].  In that study, 
experimental gingivitis was achieved by disengaging all oral hygiene practices for 21 
days in healthy subjects.  The development of gingivitis varied by individual and 
occurred as early as 10 days in some subjects.  By 21 days all participants showed 
clinical signs of gingivitis.  Following the experimental phase, oral hygiene practices 
were reinstituted resulting in the return to health in about 1 week[17]. 
The experimental gingivitis model has been used ubiquitously over the past 50 years to 
measure a variety of outcome variables.  One of these outcome variables is whether age 
plays a role in susceptibility to gingivitis.  In an experiment by Holm-Pedersen et al. [22], 
gingivitis developed more rapidly and more severely in elderly than in young persons.  
The authors suggest that with age comes an altered host response to the bacterial plaque.  
The effect of age on the host response to plaque accumulation was confirmed by Matsson 
[23], who compared pre-school aged children with young adults.  The author found that 
the younger group had a statistically significantly lower amount of gingival exudate and 
gingival bleeding than the older group.  Winkel et al. [24] tested the effect of age on the 
rate of development of gingivitis in persons not susceptible to periodontal destruction.  
The findings of this study were that in individuals not susceptible to periodontal 
destruction, age was not a factor in the development of experimentally induced gingivitis.  
Winkel et al. and Matsson use different classifications of age, making direct comparisons 
of their studies difficult.  Thus, there may be a critical age difference required to detect a 
true difference in gingivitis susceptibility to plaque accumulation. 
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The experimental gingivitis model has also been used to elucidate the histopathologic and 
immunologic features of gingival inflammatory changes.  Payne et al. [21, 25] used the 
experimental gingivitis model to describe the pathologic alterations in gingival tissues in 
early plaque accumulation.  They found that within the first 8 days of plaque 
accumulation, a lesion resembling a delayed hypersensitivity developed.  Seymour et al. 
[26] took biopsies at four time points through a 21-day oral hygiene abstention study and 
found that the nature of the composition of the infiltrate did not change significantly, as 
the degree of inflammation increased.   
Another use of the experimental gingivitis model was to evaluate techniques and 
procedures to reverse gingivitis or to mitigate its onset.  Bosman and Powell [27] 
demonstrated that a once daily rinse with 0.2% chlorhexidine (CHX) mouthrinse regained 
gingival health in 4 days versus 10 days when only brushing was performed.  Gusberti et 
al. [28] investigated the ability of two therapeutic mouth rinses, 0.12% CHX and 1% 
hydrogen peroxide (H2O2), to mitigate the development of gingivitis when all other oral 
hygiene measures were removed.  They found 0.12% CHX to significantly reduce 
gingivitis incidence, plaque, bleeding on probing, and specific facultative and obligate 
anaerobes compared to a placebo.  Conversely, 1% H2O2 did not have a significant 
difference over the placebo[28].  Ultimately, these types of studies aid in distinguishing 
the therapeutic value of different chemotherapeutic agents in treating gingivitis.  
The early experimental gingivitis studies hinted at the possibility of differences in subject 
susceptibility to plaque accumulation.  This response variability was interpreted as related 
to differences in plaque accumulation rates or differences in microbial composition[17, 
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18].   More recently, Trombelli et al. [29] in an experimental gingivitis trial were able to 
identify two subgroups of subjects that differed in their response to similar plaque 
exposure.  These were labeled the “High Responder” (HR) and “Low Responder” (LR).  
The identification of these two subpopulations was based on their amount of GCF 
volume.  This finding supports the hypothesis of the existence of host-related factors 
implicated in the individual variability of the inflammatory response to plaque.  The 
implication of susceptibility to gingivitis due to a subject’s genetic make-up or host 
response versus a purely microbial reaction has changed how the disease process is 
studied.  More efforts are looking into the effect of genetic variation and other factors that 
could further elucidate the pathogenesis of gingivitis. 
2.2 Peri-implant Mucositis 
2.2.1 Definition and Prevalence 
The definition of peri-implant mucositis is inconsistent in dental literature[30].  The 
different definitions are described in the Table 1.  Roos-Jansåker and colleagues [4] 
evaluated 216 patients and 987 implants after 9-14 years after baseline (one-year post 
delivery of prosthetic suprastructure).  They found 79.2% of patients and 42.2% of 
implants had peri-implant mucositis1.  Another study by Fransson et al. [31] selected a 
group of 82 subjects previously identified as having progressive bone loss in 1 or more 
implants beyond normal physiologic remodeling 1 year after loading.  The prevalence of 
                                                        
1 Prevalence values were taken from Table 8, where BOP was detected at implant level or 
patient level at implants where no bone loss was identified between 1-year radiographic 
control and final examination.  If prevalence was determined by presence of Bleeding on 
Probing and Pocket Probing Depth >/= 4mm irrespective of bone levels then prevalence 
would be 76.6% at the patient level and 48.1% at the implant level (Table 6).  
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peri-implant mucositis on implants with no additional bone loss after baseline (n=285 
implants) was 90.9% at implant level analysis. 
Table 1. Definitions of peri-implant mucositis in the current literature. 
Author Conditions defined as peri-implant mucositis 
Albrektsson and 
Isidor [3] 
A reversible inflammatory reaction in the soft tissues surrounding a 
functioning implant with no loss of supporting bone 
Roos-Jansåker et 
al. [4, 32] 
When one or more of the following parameters are satisfied and no 
radiographic bone loss beyond 3 threads after 1 year of loading: 
• Bleeding on Probing 
• Suppuration on probing 
• Pocket Probing Depth ≥ 4mm 
• No radiographic bone loss beyond 3 threads after 1 year of 
loading 
Ferreira et al. 
[33] 
When one or more of the following parameters are satisfied and no 
radiographic bone loss beyond 3 threads after 1 year of loading: 
• Bleeding on Probing 
• Suppuration on probing 
• Pocket Probing Depth ≤ 4mm 
• No radiographic bone loss beyond 3 threads after 1 year of 
loading 
Karbach et al. 
[34] 
When both of the following parameters are satisfied: 
• Bleeding on Probing 
• Pocket Probing Depth ≥ 5mm 
Koldsland et al. 
[35, 36] 
When both of the following parameters are satisfied: 
• Bleeding on Probing 
• No bone loss 
Maximo et al. 
[37] 
When one or more of the following parameters are satisfied and no 
radiographic bone loss beyond 3 threads after 1 year of loading: 
• Bleeding on Probing and/or gingival marginal bleeding 
• No radiographic bone loss beyond 3 threads after 1 year of 
loading 
6th, 7th, and 8th 
European 
Workshops on 
Periodontology 
[38-40] 
Inflammatory lesion limited to the mucosa seen clinically as: 
• Soft tissue redness 
• Edema 
• Bleeding on Probing 
• No bone loss subsequent to time of placement of prosthetic 
suprastructure “baseline” 
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A recent systematic review and meta-analysis by Atieh et al. [41] found 63.4% of 
subjects and 30.7% of implant sites had peri-implant mucositis.  As demonstrated, the 
prevalence of peri-implant mucositis cited in the literature varies dramatically.  This 
variability could be explained by the difference in the methods to diagnose this condition.  
2.2.2 Etiology 
Peri-implant mucositis is caused by bacterial plaque.  To establish the relationship 
between plaque formation and inflammation around implants, Pontoriero et al. [7] 
conducted a three-week experimental gingivitis peri-implant mucositis study in partially 
edentulous subjects restored with dental implants.  Phase contrast microscopy was used 
to evaluate submucosal and subgingival plaque samples.  Coccoid cells, motile rods, and 
spirochetes were found in similar proportions at baseline and at the end of the three-week 
experimental period on both the implants and teeth.  The period of oral hygiene 
abstention demonstrated the same cause and effect relationship between plaque 
accumulation and inflammation for implants and mucositis as for teeth and gingivitis.  
The results were similar to those found decades earlier by Löe et al. [17] and Theilade et 
al.[18].  A more recent study by Salvi et al. [10] also confirmed the cause and effect 
relationship between plaque formation and inflammation around the soft tissues of 
implants.  In this study the peri-implant mucosa appeared to have a stronger response to 
plaque compared to the gingiva.  Nonetheless, a well-established causal relationship 
between plaque accumulation and peri-implant mucosal inflammation has been 
consistently validated. 
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Oral bacteria colonize on the implant as early as 30 minutes to two weeks following 
implant placement.  Furthermore, the microbial flora at implants presents a composition 
almost identical to the adjacent teeth[42, 43].  This may suggest that in partially dentate 
patients, adjacent pockets harboring periodontal pathogens can act as a reservoir for 
colonization and establishment of a microflora that may not be supportive of mucosal 
health[44].   
Colonization of the implant occurs similarly to that of a tooth.  When the implant is 
exposed into the oral environment, a salivary pellicle forms on the surface.  The pellicle 
forming on a titanium surface is similar to that forming on enamel, including salivary 
alpha-amylase and proline-rich proteins[45].  The “pristine” pockets of a newly inserted 
titanium implant abutment are not only colonized rapidly, but with a complex subgingival 
microflora that mirrors the subgingival plaque of shallow gingival crevices[2].   
There are two differences between bacterial colonization on teeth and implants that have 
been identified thus far.  First, the numbers of the red and orange complex bacteria, while 
present, appear to be lower on implant sites than for tooth sites[2].  Quirynen et al. [2] 
explained this by suggesting that some taxa are able to colonize a clean site on their own, 
while other taxa require the establishment of appropriate conditions by “pioneer” species.  
In addition, Buchmann et al. [46] found that implants can be colonized by a complex 
microflora that included Porphyromonas gingivalis and Aggregatibacter 
actinomycetemcomitans.  However, this microbial colonization was compatible with peri-
implant mucosal health.  The second difference in bacterial colonization of teeth and 
implants is the specific bacterial profile in the presence of periodontitis and peri-
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implantitis.  Bacterial species not traditionally found in periodontitis such as 
staphylococci, enteric species, and yeasts have been isolated at implant sites with peri-
implantitis [47, 48].  Therefore, while several studies show similarities in the bacterial 
colonization of teeth and implants, there is evidence that the quantity and quality of this 
colonization may differ. 
In a study designed to explore potential differences of the bacteria at sites of peri-implant 
health, peri-implant mucositis, and peri-implantitis, Renvert et al. [49] looked at 40 
species from 213 subjects and 976 implants using the checkerboard DNA-DNA 
hybridization method.  The only statistical difference in bacteria was found with 
Eikenella corrodens, which was higher in peri-implant mucositis when compared to 
healthy peri-implant mucosal samples.  The prevalence of P. gingivalis, Tannerella 
forsythia, Treponema denticola, and A. actinomycetemcomitans were low and did not 
differ by implant status.  This study demonstrated that there were essentially no 
differences in the microbial profile between implant status, nor between teeth and implant 
when teeth were present.  This may suggest that different pathogens than those studied 
were responsible for the differences in implant status or that implant status may be more 
influenced by specific host immune factors[49]. 
2.2.3 Normal Histology of the Peri-implant Mucosa 
The histological features of peri-implant mucosa in health include a keratinized oral 
epithelium continuous with a thin barrier epithelium (similar to the junctional epithelium 
at teeth) that attaches to the implant surface by hemidesmosomes.  The barrier epithelium 
is approximately 2mm long, which is then continuing with a connective tissue attachment 
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(also attaching via hemidesmosomes to a titanium oxide implant surface [50]) that is 
between 1 to 1.5 mm long.  While the principal fibers of teeth invest in the root 
cementum and fan out in lateral, coronal and apical directions from the root, the implant 
equivalent fibers invest in the bone crest and run parallel to the implant[51].  Differences 
in the vascular supply are also evident between the gingiva and the peri-implant mucosa.  
The vascular supply for the gingiva originates from the periosteum and the periodontal 
ligament.  The vascular supply for the peri-implant mucosa comes solely from the 
periosteum[52].  Leukocytes are present in small numbers in a normal reaction to the 
biofilm present around implants, which is similar to that found in healthy gingiva[9].  The 
connective tissue around implants was found by Berglundh et al. [9] to have greater 
collagen and lower density of fibroblasts than the corresponding gingival connective 
tissue.  Despite these noted differences, the peri-implant mucosa and gingiva are 
remarkably similar.   
As outlined previously for teeth, if sufficient plaque is allowed to accumulate around the 
implants, mucositis will ensue.  Animal[5, 9, 53] and human[7, 8] studies have shown a 
comparable reaction to an experimental biofilm accumulation in gingiva and soft tissues 
adjacent to dental implants, when examined both clinically and histologically.  This is 
described in more detail in section 2.2.4.  
Peri-implant mucositis is a reversible inflammatory process [54].  Evidence supports that 
a persistent inflammatory condition may progress to peri-implantitis[5, 6, 55] – an 
irreversible condition, with accompanying bone loss[3].  Similarly to what has been 
reported for gingivitis and periodontitis, not all implants with mucositis progress to 
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implantitis.  Nonetheless, mucositis appears to be a required state prior to the 
development of peri-implantitis[54].  
2.2.4 Experimental Peri-implant Mucositis in Animal Studies 
The experimental peri-implant mucositis model was largely used to determine the 
histopathological features of the inflammatory response in the peri-implant mucosa 
versus gingiva.  Ericsson et al. [53] in a dog model, induced plaque accumulation for 3 
months at teeth and implant sites.  The long-standing plaque accumulation resulted in the 
establishment of an inflammatory cell infiltrate in both the gingiva and peri-implant 
mucosa.  The two lesions had several commonalities including: the length of the 
junctional epithelium, the percent volume in the infiltrate connective tissue (ICT), the 
vascular structures, and the prevalence of plasma cells.  However, the peri-implant 
mucosa had a larger average distance from free margin to bone crest (4.2mm versus 
3.2mm), a larger apical extension of the ICT (1.2mm versus 0.9mm), and a larger 
residual tissue of the inflammatory cell infiltrate (nerves, matrix, lymph, etc.) when 
compared to the gingival unit.  The gingiva had larger percent volumes of fibroblasts, 
macrophages, lymphocytes and PMNs in the ICT.  These results imply that the mucosal 
tissue may be less effective in preventing the apical propagation of the inflammatory 
infiltrate than gingiva[53]. 
Using a similar experimental model, Berglundh et al. [9] evaluated the changes of 
gingiva and peri-implant mucosa after 21 days of plaque accumulation.  The peri-implant 
mucosa and gingiva had similar reactions to early plaque formation.  Both had an 
increase in leukocyte transmigration, similar apical extensions of the ICT, and similar 
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volumes of inflammatory cells in the connective tissue lesions.  The results of the study 
point out that teeth and titanium abutments acquire similar plaque quantity after 21 days 
of accumulation, and that both gingiva and peri-implant mucosa respond similarly to the 
accumulated plaque[9].  
The beagle dog model was used to explore the nature of lesions resulting from 
subgingival and submucosal ligature placement for six weeks[5].  Clinical evaluation 
demonstrated that signs of tissue destruction were more pronounced at implants than 
teeth.  Biopsies revealed that the implants had a larger soft tissue lesion than teeth.  The 
inflammatory infiltrate on teeth was contained in the connective tissue whereas lesions on 
the implant site extended into the bone marrow [5].  This study suggests that long lasting 
inflammation in the peri-implant mucosa can progress faster into the supporting bone 
when compared to teeth.  
In summary, the series of experiments utilizing the dog model indicate that peri-implant 
mucosa and gingiva respond similarly under conditions of plaque accumulation from a 
clinical perspective.  However, structural differences between the peri-implant mucosa 
and gingiva may render the peri-implant mucosa less effective in preventing the 
progression of an inflammatory infiltrate.   
2.2.5 Experimental Peri-implant Mucositis in Human Studies 
A human experimental peri-implant mucositis model by Pontoriero et al. [7] sought to 
compare clinically and microbiologically gingiva and peri-implant mucosa after three 
weeks of oral hygiene abstention.  The results of this study showed no differences in any 
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of the clinical parameters or in the composition of the microbiota between peri-implant 
mucosa and gingiva.   
Similarly, Zitzmann et al. [8] investigated the soft tissue reactions to “de novo” plaque 
accumulation over a three-week period in humans.  In this study, 12 subjects, each with 
two implant sites and two control teeth sites, had two biopsies taken at baseline and after 
three weeks of plaque formation.  From these biopsies, histological, histometric, and 
immunohistochemical evaluations were performed.  The clinical parameters evaluated 
(PlI and mGI) were not different between tooth and implant sites.  On histological 
observations both gingiva and peri-implant mucosa had large cell infiltrates present in the 
connective tissue lateral to the junctional epithelium.  Comparisons were made with 
histomorphometry and immunohistochemistry.  No differences in the infiltrate between 
the gingiva and the peri-implant mucosa were observed at any time point.  However, the 
authors point out that mean cell densities in the infiltrate of the gingiva were consistently 
higher than in the peri-implant mucosa[8].  Zitzmann and Pontoriero both support the 
concept that both gingiva and peri-implant mucosa have a similar inflammatory response 
to plaque accumulation.   
Salvi et al. [10] used an experimental gingivitis model to clarify the pathogenesis of 
gingival/mucosal inflammation with regard to specific clinical, microbiological, and host-
derived factors.  As stated earlier, they found a comparable cause and effect relationship 
regarding bacterial challenge and host response around both natural teeth and implants.  
A stronger inflammatory response to plaque accumulation was seen in the mucosa 
surrounding implants versus natural teeth (i.e. statistically significant increase in GI, 
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Pocket Probing Depth [PPD], and MMP-8).  No difference between the subgingival and 
the submucosal microbiota was observed.  Additionally, the authors examined the 
response to reinstitution of oral hygiene measures on the resolution of inflammation.  
Reversibility was seen at the biomarker level for both mucositis and gingivitis.  The 
authors found that 3 weeks of resumed plaque control appears insufficient to bring 
gingival and peri-implant mucosa back to baseline levels[10]. 
2.3. Clinical Assessment of Gingivitis and Peri-implant Mucositis 
2.3.1 Gingival Crevicular Fluid 
The estimation of the gingival inflammatory response to plaque accumulation has 
traditionally relied on very subjective assessments (i.e. Gingival Index).  Quantitative 
analysis of the GCF has been used as an objective measure of the inflammatory status of 
gingiva [56-58].  GCF, in addition to epithelial cells and leucocytes, contains transudates 
and exudates of interstitial fluid, which includes plasma proteins, antibodies, complement, 
and protease inhibitors.  GCF flow has been found to increase as gingival inflammation 
increases [59, 60].  Also, qualitative analysis of GCF has been used to determine pro-
inflammatory cytokine levels [61].   
Two methods have been utilized for quantitating GCF volume:  the ninhydrin area 
method (NAM) and the Periotron.  The NAM relies on staining serum alpha-amino 
proteins absorbed on a filter paper with ninhydrin and quantifying the resulting stained 
area.  The Periotron measures electrical capacitance of the fluid absorbed on the filter 
paper strip, which changes in dielectric insulating properties as the quantity of fluid 
absorbed changes[57].  There have been several versions of the Periotron:  the Periotron 
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600, Periotron 6000, and the most recent Periotron 8000.  The Periotron is most 
appropriate to evaluate longitudinal changes of GCF in a particular individual, but not 
between individuals[62].   
2.3.1 Bleeding on Probing 
Bleeding on probing (BOP) around teeth has long been one of the primary clinical 
indicators of inflammation.  Lang et al. [63], evaluated BOP as a potential predictor for 
future attachment loss.  Lang found an increasing incidence of BOP corresponded with 
clinical attachment level loss of ≥ 2 mm over two years.  However, the presence of BOP 
was not a highly sensitive indicator of disease.  Rather, the absence of BOP showed a 
nearly 100% predictability for health.  
BOP has been also evaluated around dental implants.  In an experimental peri-implant 
mucositis and experimental peri-implantitis study, Lang et al. [64] demonstrated that 
healthy peri-implant sites had zero BOP, sites with experimental peri-implant mucositis 
had a mean BOP of 66.7%, and sites with experimental peri-implantitis had a mean BOP 
of 90.9%.  Thus, destruction of peri-implant tissues was found to be associated with BOP.   
To answer the question of how reliable BOP is as a predictor of future attachment loss 
around implants, Jepsen et al. [65] evaluated 25 patients with 54 implants (mean loading 
time of 41 months).  A minimum threshold of 1mm of attachment loss was selected to be 
positive for site breakdown.  BOP was found to have a high negative predictive value for 
peri-implant attachment loss (82% at the implant level and 97% at the site level).  
Similarly to teeth, the absence of BOP around implants can serve as an indicator for 
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stable peri-implant conditions[65].  When the threshold for disease progression is defined 
as an annual increase in PPD ≥ 0.5mm or 2.5mm in 5 years, BOP at ≥ 50% of sites had a 
specificity of 100% (compared to 73% for teeth) and a positive predictive value of 100% 
(compared to 40% for teeth)[66]. 
Costa et al. [55] performed a retrospective study on a group of patients identified as 
having peri-implant mucositis five years earlier.  In these patients the presence of BOP 
was significantly associated with further breakdown to peri-implantitis at five years.  
Specifically, subjects who had ≥ 50% of sites with BOP had an odds ratio (OR) of 17.69 
for developing peri-implantitis.   
Thus, these results seem to indicate that BOP may be a predictor for peri-implant bone 
loss.  However, gingival and peri-implant mucosa are structurally different and lighter 
pressure during probing around implants has been recommended.  Gerber et al. [67] 
showed the mean BOP percentage at implants (13.7%) and teeth (6.6%) increase as the 
probing pressure increased from 0.15N to 0.25N.  The authors conclude that a probing 
force of 0.15N should be applied around implants to avoid false positive BOP[67].  While 
BOP as a predictor of disease activity is limited, it may be the most useful clinical 
predictor we have during implant maintenance programs. 
There are multiple methods to measure gingival and peri-implant mucosal bleeding due 
to inflammation.  The Angulated Bleeding Index (AngBI) [68], the method by which the 
periodontal probe is placed to the level of the marginal gingiva at a 60-degree angle, is 
one example.  In an experimental gingivitis model, this method has been shown to be a 
sensitive indicator of early changes in gingival inflammation [68].  A modification of this 
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technique was recently described by Trombelli et al. [29] and is known as the Angulated 
Bleeding Score (AngBS).  While this method has been used in several experimental 
gingivitis studies[29, 68], it has yet to be employed in an experimental peri-implant 
mucositis model. 
2.3.3 Gingival Index 
The evaluation of inflammation and diagnosis of gingivitis and mucositis is not only 
based on BOP.  Clinical evaluation of the color and texture of the gingiva and mucosa 
provide valuable information as to the inflammatory status of the soft tissue. The 
accuracy of such scales is imperative for prevalence statistics in epidemiological studies.  
The Periodontal Index (PI) System developed by Russell [69] provided a scale that 
ranged from health to terminal periodontal disease.  The parameters of this scale were as 
follows: 
0 = Negative.  There is neither overt inflammation in the investing tissues nor loss 
of function due to destruction of supporting tissue. 
1 = Mild Gingivitis.  There is an overt area of inflammation in the free gingiva, 
but this area does not circumscribe the tooth. 
2 = Gingivitis. Inflammation completely circumscribes the tooth, but there is no 
apparent break in the epithelial attachment. 
6 = Gingivitis with Pocket Formation.  The epithelial attachment has been broken 
and there is a pocket (not simply due to swelling of the free gingiva).  There 
is no interference with normal masticatory function, the tooth is firm in its 
socket, and has not drifted. 
8 = Advanced Destruction with Loss of Masticatory Function.  The tooth may be 
loose; may have drifted; may sound dull on percussion with a metallic 
instrument; and may be depressible in its socket. 
 
Essentially a mean score below 2 would be considered in a range of health to gingivitis, 
while a score above 2 would be considered periodontitis.   
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The most widely used and accepted classification system was developed by Löe and 
Silness[15].  The criteria for the GI System proposed was as follows: 
0 = Absence of inflammation. 
1 = Mild Inflammation.  Slight change in color and little change in texture. 
2 = Moderate Inflammation.  Moderate glazing, redness, edema, and hypertrophy.  
Bleeding on pressure. 
3 = Severe Inflammation.  Marked redness and hypertrophy. Tendency to 
spontaneous bleeding.  Ulceration. 
 
In an effort to define parameters more appropriate for peri-implant mucosa, Mombelli et 
al. [70] applied a modified Sulcus Bleeding Index (mBI), which is often referred to as 
modified Gingival Index (mGI), to describe the level of inflammation.  In other words, 
the mBI replaces GI for implants.  The criteria for the mBI system proposed was as 
follows: 
0 = No bleeding when a periodontal probe is passed along the mucosal margin 
adjacent to the implant. 
1 = Isolated bleeding spots visible. 
2 = Blood forms a confluent red line on the margin. 
3 = Heavy or profuse bleeding 
 
Unfortunately, utilization of either the GI or mBI to describe the inflammation around the 
peri-implant mucosa requires the investigator to sweep the mucosal margin with a 
periodontal probe.  This becomes a problem in an experimental gingivitis and mucositis 
study where the objective is undisturbed plaque formation.  Trombelli et al. [29] 
conducted an experimental gingivitis study in which the GI system is modified to remove 
the bleeding on probing component.  In this study, subjects were subjectively assessed as 
to whether there was an absence of inflammation (GI = 0); the presence of mild 
 22
inflammation, or moderate inflammation solely due to observation of the gingival color 
and level of edema (GI = 1 or 2); and potentially on spontaneous bleeding if it occurred 
(GI = 3).  The limitation of this method is the ability to distinguish GI = 1 or 2 due to the 
elimination of the bleeding component.   
2.3.4 Plaque Index 
The accumulation of bacterial plaque on teeth and implants as the causal agent for 
gingivitis and mucositis is well established.  The most widely used and accepted index 
system for the quantification of bacterial plaque, and thus the measure of a subject’s oral 
hygiene status, was developed by Silness and Löe[71].  The Plaque Index (PlI) System 
was proposed as follows: 
0 = No plaque.  
1 = A film of plaque adhering to the free gingival margin and adjacent area of the 
tooth.  The plaque may be seen in situ only after application of disclosing 
solution or by using the probe on the tooth surface. 
2 = Moderate accumulation of soft deposits within the gingival pocket, or on the 
tooth and gingival margin which can be seen with the naked eye.  
3 = Abundance of soft matter within the gingival pocket and/or on the tooth and 
gingival margin plaque. 
 
Mombelli et al. [70] also supplied a modification to the Plaque Index (mPlI) in order to 
make it more fitting for peri-implant mucosa.  The criteria for the mPlI system proposed 
was as follows: 
0 = No detection of plaque. 
1 = Plaque only recognized by running a probe across the smooth marginal 
surface of the implant.  Implants covered by titanium spray in this area 
always score 1. 
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2 = Plaque can be seen by the naked eye. 
3 = Abundance of soft matter. 
 
The mPlI suffers from the same limitations described above with the GI and mBI, where 
in the context of certain experimental gingivitis and mucositis models, sweeping the 
plaque retained on an implant or tooth would interfere with the experimental design.   
Ultimately, the use of the standard PlI described by Silness and Löe[71], which permits 
the use of disclosing solution in order to distinguish between a score of 0 or 1, allows for 
plaque to be quantified and remain undisturbed.   
2.4 Risk Factors for Peri-implant Diseases 
Many studies have attempted to identify risk factors for peri-implant disease.  Often the 
outcome variable is implant loss.  This underestimates the true impact of the risk factor 
on peri-implant disease, as implant loss is the last and most severe stage in the disease 
process.   When the literature reports peri-implant disease as an outcome variable, it is 
often referring to peri-implantitis.  Less frequently will a study separate out peri-implant 
mucositis as an outcome of interest.  It has already been described that peri-implant 
mucositis is a prerequisite stage prior to disease progression to peri-implantitis.  
Therefore, it must be inferred that a risk factor for implant loss and/or peri-implantitis 
must also be a risk factor for peri-implant mucositis.  Herein, unless explicitly stated as a 
risk for peri-implant mucositis, the outcome variable will be noted as peri-implant disease, 
intended to include both peri-implant mucositis and peri-implantitis.  The literature has 
identified four main risk factors for peri-implant disease:  poor oral hygiene; history of 
periodontitis; smoking; and uncontrolled diabetes. 
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2.4.1 Poor Oral Hygiene 
The measure of oral hygiene is determined by plaque control, which is measured by the 
PlI described previously.  Several studies detailed in section 2.2.4 established the 
relationship between bacterial challenge (plaque accumulation) and host response 
(gingival inflammation), and demonstrated a similar response around both natural teeth 
and implants[7, 8, 10].  Few studies take this relationship further and explicitly explore 
poor oral hygiene as a risk factor to peri-implant mucositis.  However, in their 
investigation to elucidate risks for peri-implant disease in 212 Brazilian subjects, Ferreira 
et al. [33] found oral hygiene to be an important factor in both peri-implant mucositis and 
peri-implantitis.  The odds ratio for peri-implant mucositis and peri-implantitis in patients 
with poor oral hygiene were 1.9 (95% CI 1.2-2.3) and 3.8 (95% CI 2.1-6.8), respectively.  
This increases to 2.9 (95% CI 2.0-4.1) and 14.3 (95% CI 9.1-28.7) for peri-implant 
mucositis and peri-implantitis, respectively, for very poor oral hygiene.  This study 
suggests that as oral hygiene worsens, patients are more likely to develop peri-implant 
mucositis and peri-implantitis. 
2.4.2 History of Periodontitis 
There is evidence indicating that patients with a history of periodontal disease are at a 
significantly greater risk for peri-implant diseases[32, 72, 73].  In a 10-year prospective 
study of patients who were under regular supportive periodontal therapy (SPT), Karoussis 
et al. [74] found a significant difference in the incidence of peri-implantitis in patients 
who lost their teeth due to periodontal disease (28.6%) when compared to individuals 
who lost their teeth due to other reasons (5.8%).  In a systematic review and meta-
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analysis by Schou et al. [75], the authors found a significant increase in the number of 
patients with peri-implantitis after a 10-year follow-up, when their tooth loss was due to 
periodontal disease, risk ratio (RR) 9 (95% CI 3.94-20.57).  Marginal bone loss after 5 
years around implants in patients whose tooth loss was due to periodontitis was 
significantly increased compared to patients whose tooth loss was due to other reasons.  
Ferreira et al. [33] reported an OR of 3.1 (95% CI 1.1-3.5) for patients with a history of 
periodontitis to develop peri-implantitis.  This relationship was not found to be 
statistically significant for peri-implant mucositis.  In their five-year retrospective study 
of patients diagnosed with peri-implant mucositis at baseline, Costa et al. [55] found the 
OR for these patients to develop peri-implantitis was 9.2 (95% CI 1.53-55.32) if they 
currently had periodontitis.  The OR increased to 11.43 (95% CI 1.11-117.33) if these 
patients with periodontitis were not in a routine maintenance program. 
Simonis et al. [76] evaluated the long-term results of implants in 55 patients with 131 
Straumann tissue level implants after 10-16 years.  The long-term survival rate was 
82.94%, with frequent biological (mucositis and implantitis) and technical complications.  
Patients with a history of periodontitis showed a prevalence of peri-implantitis of 37.93%, 
while in subjects without a history of periodontitis, peri-implantitis was present in 
10.53% of the cases.  This translated to an OR of 5.1 (95% CI 1.92-14.06).  The literature 
consistently found that subjects with history of periodontitis were much more likely to 
develop peri-implant disease than persons without periodontitis. 
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2.4.3 Smoking  
Smoking is a risk factor extensively evaluated in the implant literature. Several studies 
have demonstrated that smokers have significant increased risk for peri-implant 
mucositis[34, 77, 78].  Karback et al. [34] reported smoking to be associated with per-
implant mucositis with an OR of 3 (95% CI 1.141-7.916).  In a prospective study of 24 
implants in 10 smokers and 18 implants in 4 nonsmokers of at least one-year follow-up, 
Ataoglu et al. [79] found that smokers had a significant increase in the inflammation-
related clinical parameters PPD, mPI, mGI, and GCF flow rate.   
A retrospective study by Hass et al. [80] evaluated 1366 implants in 421 patients (366 
implants in 107 smokers and 1,000 implants in 314 nonsmokers) with an average recall 
time of 22 months.  Smokers were found to have increased bleeding index, PPD, degree 
of peri-implant mucosal inflammation, and radiographic bone loss.  These differences 
were significant in the maxilla compared to mandible in smokers and in the maxilla 
between smokers and nonsmokers.  These findings may indicate that implants in the 
maxilla are more susceptible to the effects of smoking than in the mandible.    
Fransson et al. [31] evaluated 82 subjects previously identified as having peri-implant 
bone loss and described the clinical characteristics of the peri-implant mucosa.  Subjects 
identified as smokers had a statistically significant difference in mean number of affected 
implants when compared to nonsmokers, 3.2 versus 1.7 respectively.  Additionally, 
smokers had a significantly greater prevalence of implants with suppuration (25% versus 
6%), greater number of PPD ≥ 6mm (40% versus 20%), and an OR of 2.2 (95% CI 1.5-
3.3) of having a history of progressive bone loss around implants[31].  A systematic 
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review by Strietzel et al. [81] found implant failure in smokers had an implant related OR 
of 2.25 (95% CI 1.96-2.59), and a patient related OR of 2.64 (95% CI 2.26-5.77).  Thus 
indicating that smokers had a significantly increased risk of biological complications 
around implants.   
There is mounting evidence that smoking in combination with a history of periodontal 
disease may add additional risks than either factor alone[82, 83].  Heitz-Mayfield and 
Huynh-Ba [83] evaluated how a history of periodontitis and smoking both separately and 
in combination affected dental implants.  They found that there was an increased risk of 
peri-implantitis in smokers versus nonsmokers (OR ranged from 3.6 to 4.6) and an 
increased risk of peri-implantitis in patients with a previous history of periodontitis.  In a 
10-year retrospective analysis, Aglietta et al. [82] evaluated implants placed in smokers 
with a history of treated periodontitis, who were also enrolled in supportive periodontal 
therapy.  Subjects with a history of treated periodontitis and smoking had lower implant 
survival rates and higher marginal bone loss than implants placed in smokers without a 
history of periodontitis[82].  This may suggest an increased risk for peri-implant disease 
and implant failure when a patient has multiple risk factors. 
2.4.4 Diabetes 
The risks of implant failure and biologic complications associated with diabetes are more 
controversial in the literature.  This may be due to a significant heterogeneity between 
studies that investigated the effects of diabetes on implant health.  While some studies 
investigate the implant outcomes for patients with poor diabetic control[33], others 
evaluated whether there are differences in implant success in patients with good diabetic 
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control[84].  Lastly, some studies do not specifically note the level of diabetic control of 
the patients[85-87].  With regard to patients with good diabetic control, Abdulwass and 
Dhanrajani [84] reported no increased risk of implant failure in patients that had HgA1c 
levels ≤ 7% and are in a supportive periodontal therapy program, when compared to non-
diabetics.  Conversely, Ferreira et al. [33] showed that patients with poor diabetic control 
have an increased risk of peri-implant mucositis and peri-implantitis.   
In studies where the level of diabetic control is not reported, the conclusions are 
controversial[85-87].  Using the results of the two studies described above as examples, 
well-controlled diabetes does not appear to cause increased risk of biologic complications 
around implants, while uncontrolled diabetes is a risk factor for peri-implant disease.  By 
not stratifying this variable, the true effect of diabetes on implants cannot be fully 
elucidated.  
3. Aim, Hypothesis and Objectives 
3.1 Aim 
The aim of the present pilot study is to evaluate and compare peri-implant soft tissue 
response to that of gingival tissue in the same subjects in a naïve condition, during de 
novo plaque accumulation, and after resolution.   
3.2. Hypothesis 
There is a different clinical response to plaque accumulation in peri-implant mucosa 
when compared to gingiva. 
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3.3 Objectives 
3.3.1 Primary Objective 
To assess changes in Plaque Index, Gingival Index, Angulated Bleeding Score, and 
Gingival Crevicular Fluid volume between peri-implant mucosa (test) and gingiva 
(control) over the two experimental phases (stimulation and resolution of inflammation).   
3.3.2 Secondary objectives 
• To describe differences between test and control at the naïve condition. 
• To describe the effectiveness of the methodology to induce plaque accumulation. 
• To describe the prevalence of complications during the experimental phase. 
  
4. Study Design and Methods 
4.1 Study design 
The study was a controlled clinical trial with a cross arch design to evaluate and compare 
the peri-implant soft tissue response to de novo plaque accumulation to that of the gingiva 
around natural teeth.  Clinical parameters were evaluated in the patients’ natural state, 
after professional debridement, over 21 days of oral hygiene abstention (experimental 
peri-implant mucositis and gingivitis) and following 21 days of re-instatement of oral 
hygiene practices. 
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4.2 Patient Selection 
The research protocol was approved by the Institutional Review Board at the University 
of Connecticut.  Participants were recruited among the patient population formerly 
treated for implant therapy at the University of Connecticut School of Dental Medicine.  
Once a patient was determined to be eligible for participation, he/she signed informed 
consent.  Participants were required to have two implants (test) in the premolar or molar 
positions and two natural teeth (control) in premolar or molar position in the same dental 
arch.  The inclusion/exclusion criteria for selecting the study participants are presented in 
Table 2.  
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Table 2. Inclusion and exclusion criteria.
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4.3 Experimental Design and Procedures 
The experimental schema is reported in Fig. 1.  
 
Figure 1.  Experimental design.  GCF = gingival crevicular fluid volume; GI = gingival 
index; PlI = plaque index; AngBS = angulated bleeding score; Sc/P = scaling and 
polishing; OHI = oral hygiene instructions; *only after the patient qualified for the study 
and agreed to participate; ^ PlI of 0 and GI of 0 needed to be achieved prior to proceeding 
with the experimental phase. 
Additional explanations for specific visits are described below: 
Screening visit:  The experimental procedure was explained and a written informed 
consent was presented for patient acceptance.  Inclusion and exclusion criteria were 
verified with a medical questionnaire, clinical oral exam, and dental radiographs.  The 
radiographs, taken only if current (within 1 year) films were not readily available for 
review, were used to determine the presence or absence of bone loss around implants and 
teeth.  The qualified patients were then provided with 56 tablets of 250 mg vitamin C 
supplement to be taken daily during the pre-trial and trial period.  The purpose of the 
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vitamin C was to prevent any possibility of a deficiency that could affect the patient’s 
susceptibility to inflammation.   
Visit 1 (day -14):  General OHI was provided to each patient.  A toothbrush, floss, and 
fluoridated toothpaste were provided to each patient (Colgate-Palmolive Company, New 
York, NY, USA).  Peripheral blood (10 mL) was collected in EDTA tubes and 
immediately stored at -80°C until further analysis (results to be reported elsewhere). 
Visit 2 (day -7):  All patients received a review of OHI, stent trial, and a second round of 
scaling and polishing if needed.  Experimental procedures were reviewed.  
Visit 3 (day 0):  Healthy gingiva (GI = 0) and excellent plaque management (PlI = 0) was 
verified.  If subjects did not satisfy this prerequisite, they were provided another round of 
scaling and polishing and oral hygiene instructions and asked to return in one week.  
Visit 6 (day +21):  Stents were collected and patients were instructed to reinstitute oral 
hygiene.  A new toothbrush and fluoridated toothpaste were provided to each patient 
(Colgate-Palmolive Company, New York, NY, USA). 
Visit 7 (day +42):  Scaling and polishing and a review of oral hygiene instructions 
followed collection of clinical parameters. 
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Clinical Parameters 
Clinical parameters were collected as listed below from the test and control sites selected 
for each patient.  
• GCF was collected as described by Trombelli et al. [29] and measured using the 
Periotron 8,000 (OraFlow Inc., Plainview, NY, USA).  The specific site was 
isolated using a cotton roll to avoid salivary contamination and gently air dried in 
an apico-coronal direction.  Supragingival plaque was not disturbed.  A sterile 
paper strip (Periopaper, OraFlow Inc,) was placed into the sulcus until mild 
resistance was sensed.  The paper strip was held in place for five seconds and 
immediately measured chair-side by the calibrated Periotron 8,000.  
• GI according to Löe and Silness [15] and the modification by Trombelli et al. 
[29], which removed the bleeding on probing component. 
• PlI according to Silness and Löe [71] and applied by the method described by 
Furuichi et al. [88].  Plaque was first identified as either visible or not visible.  If 
visible, the plaque was categorized as either a score of 2 or 3.  If not visible, a PlI 
score of 0 or 1 was determined by staining the tooth or implant with erythrosine 
solution (Red Cote, Butler, Chicago, IL, USA) using a syringe applicator.  
• AngBS was performed as described by Trombelli et al. [29].  The gingiva or 
peri-implant mucosa was lightly air-dried.  A periodontal probe was inserted into 
the sulcus at an angle of approximately 60 degrees to the long axis of the tooth or 
implant.  The scoring method was: 0 = no bleeding; 1 = bleeding after probe 
stimulation; 2 = spontaneous bleeding. 
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Stent Fabrication 
Cast models were prepared from the alginate impressions taken on visit 1.  Wax was 
placed (2 mm thick) from coronal to the height of contour to 4-5 mm apical to the 
gingival/mucosal margin on both the buccal and lingual/palatal surfaces of the test and 
control sites.  This was done to allow the plaque to accumulate undisturbed.  A duplicate 
of this altered model was made.  Stents were fabricated using 1.5 mm thermo-forming 
material (Henry Schein Inc., Melville, NY, USA) and a vacuum forming machine (Henry 
Schein Inc., Melville, NY, USA).  The stents were trimmed and adjusted as needed in the 
patient on visit 2.  Patients were instructed to insert the stent prior to brushing during the 
experimental phase.  This allowed the remainder of the dentition to be brushed without 
removal of plaque from the experimental sites.  
4.4 Data Analysis 
For the clinical parameters of GI, PlI, and AngBS, 2 recordings from each tooth and 
implant were taken.  The means were calculated for both test and control sites for each 
patient.  The averages of two readings from the Periotron 8,000 of each paper strip for the 
GCF measurement were recorded for one tooth and one implant.  The patient was 
considered as the statistical unit.  Thus, the patient was represented by a single control 
and a single test value for each parameter at each time interval.   
A minimum of 15 participants was considered necessary for statistical analysis.  This 
number of subjects for our pilot study was based on previous experimental peri-implant 
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mucositis studies in humans [7, 8, 10].  Considering 20% attrition, a total of 18 subjects 
were enrolled. 
The null hypothesis was that no significant clinical differences assessed during the 
experimental three-week period of absent oral hygiene would exist between the peri-
implant mucosa and the gingiva.  The Kolmogorov-Smirnov goodness fit test was 
computed to test the normal distribution for each parameter.  All the variables were found 
not normally distributed.  Therefore, inter-individual comparisons were performed using 
the Mann-Whitney Test.  The Wilcoxon Signed Rank Test was used to analyze intra-
individual comparisons.  The Spearman Rank Correlation Test determined correlations 
between the four clinical parameters.  Significance for all variables was set at 95% 
(α=0.05). 
5. Results 
Demographics and protocol deviations 
Eighteen patients were enrolled.  For the purpose of this report we are presenting the 
results relative to 14 completed subjects.  One participant has not yet completed the trial. 
During the study, 3 patients exited the experiment.  Patient flow is reported in Fig. 2.  
One patient was excluded from the study due to the development of an acute episode of 
swelling of the mucosal margin of a test site with drainage observed at the d.14 visit.  The 
site was immediately treated with debridement of the area, thorough irrigation and one 
week of 0.12% chlorhexidine mouth rinse.  The condition completely resolved at one 
week.  The other two participants were excluded from the study due to a change in 
medical condition unrelated to the study proceedings.   
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Figure 2.  Enrollment and subject completion flow chart. 
Demographic description of the patient population is reported in Table 3.    
Table 3. Demographic descriptions.   
 
 
Plaque Accumulation 
The clinical data of the median and range of the PlI are presented in Table 4.  Both 
control and test groups showed a statistically significant decrease in PlI from the naïve 
state (d.-14) to day 0 (d.0) (p=0.002 and p=0.008, Wilcoxon Signed Rank Test).  
Compared to d.0, there was a statistically significant increase in PlI at each time point of 
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plaque accumulation for the control and test groups over the experimental phase (Table 5, 
Fig. 3a and b).  There was statistically significantly greater plaque on d.42 than on d.0 in 
both groups (p=0.004 control and p=0.008 test, Wilcoxon Signed Rank Test).  In neither 
group was there a statistically significant difference between the d.-14 and d.42.  The 
control group had a significantly greater PlI than the test groups on d.14 and d.21 
(p=0.036 and p=0.048, Mann-Whitney Test) (Table 5 and Fig. 4).  
Table 4. Clinical data for PlI, GI, AngBS and GCF for control and test sites. 
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Table 5. Within group and between group (shaded) comparisons among median PlI 
measured at different time points in control and test groups. 
 *Not significant. ‡Significance level: < 0.05.  Mann-Whitney Test was used to determine 
significance between groups (shaded) and Wilcoxon Signed Rank Test was used for 
within group analysis. 
 
a  
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b  
Fig. 3.  Box-Whisker plot for plaque index over pre-experimental, experimental, and 
resolution phases in control (a) and test (b) groups (n =14). 
  
Fig. 4.  Box-Whisker plot for plaque index over pre-experimental, experimental, and 
resolution phases comparing control and test groups (n =14).  *Significance level:  < 0.05, 
Mann-Whitney Test used for between group analysis. 
Gingival Inflammation 
The clinical data of the median and range of the GI are presented in Table 4.  Both groups 
showed a statistically significant decrease in GI from the d.-14 to d.0 (p=0.016, Wilcoxon 
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Signed Rank Test).  Compared to d.0, there was a statistically significant increase in GI at 
each time point for the control and test groups over the experimental phase (Table 6 Fig. 
5a and b).  The GI was statistically significantly greater on d.42 than on d.0 in both 
groups (p=0.016 control and p=0.031 test, Wilcoxon Signed Rank Test).  In neither group 
was there a statistically significant difference between the d.-14 and d. 42.  Significant 
differences were not observed between the control and test groups at any time point 
(Table 6 and Fig. 6). 
Table 6. Within group and between group (shaded) comparisons among mean GI 
measured at different time points in control and test groups.  
 *Not significant. ‡Significance level: < 0.05.  Mann-Whitney Test was used to determine 
significance between groups (shaded) and Wilcoxon Signed Rank Test was used for 
within group analysis. 
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a  
b   
Fig. 5.  Box-Whisker plot for gingival index over pre-experimental, experimental, and 
resolution phases in control (a) and test (b) groups (n =14). 
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Fig. 6.  Box-Whisker plot for gingival index over pre-experimental, experimental, and 
resolution phases comparing control and test groups (n =14). 
The clinical data of the median and range of the AngBS are presented in Table 4.  The 
control group demonstrated a statistically significant increase in AngBS from d.0 to d.7, 
d.14, and d.21 (p=0.016, 0.031, and 0.008, Wilcoxon Signed Rank Test).  The test group 
demonstrated a statistically significant increase from d.0 to d.14 and d.21  (p=0.016 and 
0.018,Wilcoxon Signed Rank Test).  There were no other statistically significant 
differences in AngBS within groups over time (Fig. 7a and b).  The test group had a 
significantly greater AngBS than the control on d.42 (p=0.043, Mann-Whitney Test) (Fig. 
8).  
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a  
b  
Fig. 7.  Box-Whisker plot for angulated bleeding score over pre-experimental, 
experimental, and resolution phases in control (a) and test (b) groups (n =14). 
*Significance level:  < 0.05, Wilcoxon Signed Rank Test used for within group analysis. 
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 Fig. 8.  Box-Whisker plot for angulated bleeding score over pre-experimental, 
experimental, and resolution phases comparing control and test groups (n =14). 
*Significance level:  < 0.05, Mann-Whitney Test used for between group analysis. 
The clinical data of the median and range of the GCF are presented in Table 4.  The 
control group demonstrated a statistically significant increase in GCF between the d.-14 
and d.21 (p=0.023, Wilcoxon Signed Rank Test).  Significant differences were also seen 
between multiple time intervals (Fig. 9a).  The test group demonstrated a statistically 
significant increase from d-14 to d.7 and d.14 (p=0.016 and 0.044, Wilcoxon Signed 
Rank Test).  Additionally, statistical differences were observed from d.0 to each of the 
other time intervals in the experimental phase (Fig. 9b).  The test group had a 
significantly greater GCF than the control on d.7 (p=0.038, Mann-Whitney Test) (Fig. 10). 
 
 
 
 
 a 
b
Fig. 9. Box-Whisker plot for gingival crevicular
experimental, and resolution phases in control (a) and test (b) groups (
*Significance level:  < 0.05, Wilcoxon Signed Rank Test used for within group analysis
 
  
 fluid volume over pre-experimental, 
n =14). 
46
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Fig. 10. Box-Whisker plot for gingival crevicular fluid over pre-experimental, 
experimental, and resolution phases comparing control and test groups (n =14). 
*Significance level:  < 0.05, Mann-Whitney Test used for between group analysis. 
Correlations between PlI, GI, AngBS, and GCF volume were analyzed.  A correlation 
between GI and AngBS was found at d.21 for the test group (p=0.026, rs=0.609, 
Spearman Rank Correlation Test).  Also in the test group, a correlation between GI and 
PlI was seen at d.7 (p=0.02, rs=0.625, Spearman Rank Correlation Test).  No other 
correlations were observed between any of the clinical parameters at any time point in 
either the test or the control groups. 
6. Discussion 
The primary objective of this study was to assess changes in the PlI, GI, AngBS, and 
GCF volume between gingiva and peri-implant mucosa over a 21 day period of plaque 
accumulation (experimental phase), and following a 21 day period of resumption of oral 
hygiene measures (resolution phase).  The control and test groups demonstrated a 
significant effect of time on PlI score.  Statistically significant increases in PlI over the 
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experimental phase, and statistically significant decreases in PlI over the resolution phase 
were observed.   This finding demonstrates that the study methodology to induce plaque 
accumulation was effective.  When comparing the two groups, the PlI was significantly 
higher in the control group at d.14 and d.21 when compared to the test.  This result was 
expected.  Ceramo-metal restoration have showed lower plaque accumulation when 
compared with unrestored teeth[89].  Natural teeth accumulate more plaque than crowned 
teeth under the same conditions due to their differences in surface roughness.  The lower 
PlI in the test sites was observed despite the presence of full coverage crowns in 50% of 
the control sites.  Additionally, the median PlI scores on teeth and implants in our study 
were consistent with PlI scores reported in the other experimental peri-implant mucositis 
studies in humans[7, 8, 10]. 
This study sought to investigate differences between gingiva and peri-implant mucosa in 
their responses to plaque accumulation.  The GI, AngBS, and GCF volume are indirect 
measure of the peri-implant mucosal/gingival inflammatory response[90]. 
The control and test groups demonstrated a significant effect of time on GI score. 
Statistically significant increases in GI over the experimental phase, and statistically 
significant decreases in GI over the resolution phase were observed in both control and 
test groups.  However, there were no statistically significant differences seen in GI scores 
between gingiva and peri-implant mucosa at any time point during the pre-experimental 
phase, the experimental phase, or the resolution phase, respectively.  One of the 
limitations of this study is that for enrollment convenience we did not exclude subjects 
with full crown coverage in the control sites.  This may raise concern in relation to a 
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possible effect of the crown margin on the response of the gingival tissue.  A 
retrospective study by Carnevale et al. [91] assessed the PlI and GI of 510 crowned teeth 
and 510 natural teeth in patients under a strict maintenance program.  The results 
demonstrated that there were no differences in PlI and GI between teeth with and without 
crowns.  This held true regardless of where the crown margin was placed (supragingival, 
at the gingival margin, or subgingival).   
The lack of significant difference in GI between test and control observed in our study 
differed from the results reported by Salvi et al. [10].  In that study, statistically 
significant differences were observed between the gingiva and peri-implant mucosa 
during the experimental and resolution phases.  The peri-implant mucosa had greater GI 
than the gingiva.  One reason for this difference could be related to the methodology used 
to measure GI.  The Salvi et al. [10] study utilized the mGI described by Mombelli et al. 
[70], while in our investigation we utilized the GI method according to Löe and Silness 
[15] modified by Trombelli et al.[29].  We used this method because one of the priorities 
in this study was to leave the plaque undisturbed throughout the whole experimental 
phase.  As detailed in section 2.3.3, by removing the bleeding component, the ability to 
distinguish between a GI score of 1 or 2 is limited.  Hence, the lack of significant 
difference in GI should take into consideration that this methodology may have resulted 
in a less sensitive assessment of GI.      
The GI in both groups on d.42 was significantly greater than the GI on d.0 (baseline).  
This result, also observed by others[10], suggests that the resolution of an established 
inflammatory state may require a longer period of plaque control to return to baseline.  
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However, the GI in both groups on d.42 was not statistically different than the GI on d-14 
(naïve condition).     
The AngBS is another clinical measure of the inflammatory response to plaque 
accumulation.  Angling a periodontal probe into the marginal gingiva has been shown to 
be a sensitive indicator of early changes in the gingival condition in an experimental 
gingivitis model[68].  Other methods of measuring gingival bleeding due to inflammation 
involve probing while sweeping the marginal gingiva (thus disrupting the plaque biofilm), 
probing to the bottom of the sulcus, and probing parallel to the tooth.  Each of these 
methods have been found to elicit significantly greater number of bleeding points than 
the angled probing method.  Extrapolating these findings to peri-implant mucosa where 
the resistance to probing forces are less than gingiva[67], we would expect a significant 
overestimation of the level of peri-implant mucosal inflammation.  The AngBS was 
chosen in our study in order to provide a sensitive test of peri-implant mucosal and 
gingival inflammatory change, without disruption of plaque accumulation.  A statistically 
significant increase in AngBS was observed in both the control and treatment groups 
during the experimental phase.  However, a statistically significant decrease in AngBS 
was not seen in either group following the resolution phase.  In comparing the two groups, 
the test group had a significantly greater AngBS than the control group on d.42.  This 
finding may suggest that the peri-implant mucosa does not recover as quickly as gingiva. 
This finding was consistent with that reported by Salvi et al. [10].  The Salvi et al. study 
found that peri-implant mucosa had a statistically greater level of inflammation than the 
gingiva at d.42.  Although AngBS was not measured in their paper, the authors evaluated 
the mGI, which included a bleeding component.  Their results led to the same conclusion 
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that inflammation at peri-implant mucosal sites did not resolve as quickly as 
inflammation at gingival sites. 
The GCF volume as a clinical parameter of gingival inflammation has been demonstrated 
to have the highest correlation with PlI[29].  The GCF volume increased throughout the 
experimental phase and decreased after the resolution phase.  On d.7, the test group had a 
significantly greater GCF volume compared to the control group.  This could suggest that 
the peri-implant mucosa responds more immediately to experimental plaque 
accumulation than gingiva.  The traditional method for collecting GCF from the gingival 
or peri-implant mucosal sulcus involves the removal of supragingival plaque; after which 
a sterile paper strip is placed into the sulcus for 5 to 30 seconds[60, 92]. Supragingival 
plaque has been shown to significantly increase the GCF measurements in subjects with 
healthy gingiva[60].  However, removing the supragingival plaque would not be 
compatible with our study design of undisturbed plaque accumulation.  Thus, the 
potential influence of plaque on our GCF measurements cannot be ruled out. This is the 
first study to our knowledge that directly compares the GCF in the peri-implant mucosal 
sulcus to that of the gingival sulcus using this methodology.  Further investigations are 
needed to confirm these data.  
One of the objectives in our study was to describe the clinical parameters between the 
control and test groups in the naïve condition (d.-14).  For each clinical parameter 
evaluated at this time point, no differences were observed between the two groups.  This 
observation was never reported in previous investigations.  Previous experimental peri-
implant mucositis/gingivitis studies in humans all consider baseline to be after 
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professional debridement with oral hygiene instruction and motivation[7, 8, 10].  Their 
aim was to have baseline PlI and/or GI scores close or equal to zero prior to commencing 
the experimental phase.  In our study, by evaluating participants at their first visit 
comparisons could be made to each subsequent step in the experimental and resolution 
phases.  We found that while PlI and GI scores remained significantly elevated in both 
control and test groups when comparing d.0 to d.42, there were no differences when 
comparing d.-14 to d.42.  
The lack of significant difference for the clinical parameters analyzed in our study must 
be taken with caution due to the small sample size used.  However, these data will be 
utilized to determine the sample size in future studies. 
7. Conclusion 
In conclusion, the results from this study support a cause and effect relationship between 
plaque accumulation and clinical parameters of gingival and peri-implant mucosal 
inflammation.  These results are in agreement with those found in several experimental 
peri-implant mucositis studies in humans[7, 8, 10].  We showed that 21 days of 
undisturbed plaque accumulation results in similar clinical inflammatory responses from 
both gingiva and peri-implant mucosa.  Future studies of the GCF and plaque 
composition will further clarify whether there are any molecular and bacterial differences 
at the two experimental mucosal sites.  The reversibility of gingivitis and peri-implant 
mucositis was demonstrated by the reimplementation of oral hygiene measures over a 
second 21-day period.  Reinstitution of oral hygiene was not sufficient to restore the 
gingival/mucosal conditions observed at baseline (d.0).  However, a reduction in the 
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parameters of PlI, GI, AngBS, and GCF volume back to naïve condition levels was 
achieved at the completion of the resolution phase.  
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